BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2021

View Archived Issues

Triumvira initiates phase I/II trial of TAC-01-HER2 in relapsed or refractory solid tumors

Read More

First-in-human trial evaluates RPTR-168 in HPV-16 E6/E7-positive tumors and melanoma

Read More

AbCellera and Eli Lilly present second antibody to enter clinical development against COVID-19

Read More

First-in-human data for RZ-402 show potential for once-daily dosing

Read More

Vivace advances phase I trial of VT-3989 in solid tumors

Read More

Seqirus quadrivalent influenza vaccine Flucelvax noninferior to standard in children

Read More

Oral oncolytic reovirus RC-402 elicits potent immune responses against colon cancer

Read More

Novel GLUT5 inhibitor molecule to treat fructose-induced diseases

Read More

Study identifies four Alzheimer's subtypes

Read More

Silverback Therapeutics patents TGFBR1 inhibitors

Read More

Boswellic acid derivative inhibits Th17 cell differentiation by targeting eIF2alpha

Read More

Combination of pacritinib/sirolimus/low-dose tacrolimus for GvHD: preclinical and phase I results

Read More

Pipeline Therapeutics synthesizes muscarinic M1 receptor antagonists

Read More

BioCryst Pharmaceuticals patent details complement factor D inhibitors

Read More

Boehringer Ingelheim discovers TRPA1 antagonists

Read More

General Regeneratives patents IL-33 protein for cancer immunotherapy

Read More

FDA grants accelerated approval to Keytruda for first-line gastric or GEJ adenocarcinoma

Read More

Adagio initiates global phase II/III EVADE study of ADG-20 for the prevention of COVID-19

Read More

GB-1265: a galactin-3 inhibitor for corneal fibrosis

Read More

Revelation reports phase I data on REVTx-99

Read More

ADG-126, a novel cancer immunotherapy candidate with improved safety and efficacy

Read More

European Commission approves Xtandi for metastatic hormone-sensitive prostate cancer

Read More

Benlysta approved in E.U. for active lupus nephritis

Read More

Targeting RRM2 and mutant p53 as novel therapeutic strategy in TNBC

Read More

Moderna reports initial COVID-19 vaccine booster data with mRNA-1273 and mRNA-1273.351

Read More

Phase II trial evaluates Telomelysin, pembrolizumab and stereotactic radiation in head & neck cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing